Efficacy of 9-(2-phosphonylmethoxyethyl)adenine in the therapy of TK+ and TK- herpes simplex virus experimental keratitis.
The acyclic nucleoside phosphonate analogue PMEA [9-(2-phosphonylmethoxyethyl)adenine] is a broad spectrum antiviral agent effective against DNA viruses and retroviruses. It is particularly active against the human immunodeficiency virus and, like other phosphonylmethoxyalkyl derivatives, it also inhibits HSV-1, TK- HSV-1 and HSV-2. We have evaluated the therapeutic efficacy of PMEA in the HSV-1 and TK- HSV-1 experimental keratitis models using BVDU (bromovinyldeoxyuridine) as the reference compound. As compared to placebo eyedrops, PMEA 0.2% and BVDU 0.2% eyedrops induced a rapid and significant healing (P less than 0.005) of keratitis caused by TK+ HSV-1. Treatment with PMEA 0.2% eyedrops also reduced the severity of keratitis caused by the TK- HSV-1 (P less than 0.05), whereas BVDU 0.2% eyedrops did not affect the course of TK- HSV-1 keratitis.
Maudgal
P C
PC
Eye Research Laboratory, Katholieke Universiteit Leuven, Belgium.
De Clercq
E
E
D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000287:Administration, Topical; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004195:Disease Models, Animal; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D063065:Organophosphonates; D011817:Rabbits; D018139:Simplexvirus
D000998:Antiviral Agents; D063065:Organophosphonates; C020235:brivudine; C053001:adefovir; D001973:Bromodeoxyuridine; D000225:Adenine